PATENT CLAIM ANALYSIS

Application Number: 16036678
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "100000"]

Abstract:
The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 5-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 5-21 after stopping posaconazole.

Claim (Index 8):
The method of  claim 1 , wherein the patient is a poor or intermediate CYP3A4 metabolizer.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 95.0
- Lexical Diversity: 2.15909
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15596585', '14566412', '13973897', '14511703', '14567005']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7375350543006456
- 35 USC 102 Novelty (BERT): 0.5467410269334837
- Combined Prediction Score: 0.7184556515639294
- Mean Citation Score: 256.82629800000007
- Max Citation Score: 385.6904
- Similarity Product: 212.8321976155281

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test